“We are very pleased to announce the founding of our French subsidiary. The subsidiary is building the spine to provide innovative therapy to patients in need. We are grateful for the support of authorities, regulatory bodies, physicians, patient associations and all members of the professional medical community France and we look forward to continuing our collaboration, ” commented Florian Vogel, Commercial Director of MYR Pharmaceuticals.
About Hepcludex® (DCI = bulevirtide)
Hepcludex® represents the most advanced new clinical approach to the treatment of hepatitis B and D, and is currently the subject of a phase 3 study on the indication of chronic HDV. The drug inhibits the NTCP receptor on the surface of hepatocytes and prevents infection of healthy cells and viral spread in the liver. Hepcludex® has received the orphan drug designation for the treatment of HDV infection from the European Medicines Agency (EMA) and the United States Food & Drug Administration (FDA). In addition, the EMA has granted eligibility for the PRIORity MEdicines (PRIME) program.
The positive opinion of the EMA Committee for Medicinal Products for Human Use (CHMP) concerning the conditional marketing authorization (CMA) has been published May 29e 2020.
About MYR Pharmaceuticals
MYR Pharmaceuticals is headquartered in Bad Homburg (Germany). The company started operations in 2011 and is supported by venture capitalists such as High-Tech-Gründerfonds and Maxwell Biotech Venture Fund. More information available at http://myr-pharma.com/.
Thomas Christély, financial director
Phone: +49 (0) 6172-4959811
E-mail: [email protected]